)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
LIDDS
LIDDS (LIDDS) investor relations material
LIDDS has been delisted
LIDDS Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary20 Nov, 2025
Executive summary
No net sales were recorded for Q3 or the nine-month period; the company remains pre-revenue.
Operating and net losses narrowed year-over-year, with Q3 net loss at -891 KSEK and nine-month net loss at -2,935 KSEK.
Major strategic shift: development of Nanodotax, Nanoimod, and NOV202 projects ceased in April 2025.
Board determined equity was less than half of share capital, triggering a balance sheet for liquidation and a control meeting; decision made to continue operations.
Financial highlights
Q3 2025: Net sales 0 KSEK (unchanged), operating result -876 KSEK (improved from -1,061 KSEK), net result -891 KSEK (vs. -877 KSEK), EPS -0.01 SEK (unchanged).
Jan–Sep 2025: Net sales 0 KSEK, operating result -2,967 KSEK (improved from -3,453 KSEK), net result -2,935 KSEK (vs. -3,296 KSEK), EPS -0.02 SEK (vs. -0.03 SEK).
Cash flow from operating activities for Jan–Sep 2025 was -2,949 KSEK (improved from -4,451 KSEK).
Cash and cash equivalents at period end: 1,733 KSEK (down from 6,552 KSEK year prior).
Equity ratio at 75% as of September 30, 2025; equity at 1,492 KSEK.
Outlook and guidance
Cash is expected to last through Q1 2026 if current cost levels are maintained; additional financing will be needed if costs rise.
Extraordinary general meeting in December to decide on reducing share capital to 500 KSEK to restore equity.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from LIDDS
- Losses narrowed but all key projects were terminated and future operations remain uncertain.LIDDS
Q2 2025 - No sales, ongoing losses, and strategic refocus define LIDDS's 2024 interim results.LIDDSQ3 2024
- No sales, narrowed loss, and cost cuts mark LIDDS' H1 2024 after Noviga acquisition.LIDDSQ2 2024
- Project terminations and asset write-downs put LIDDS in liquidation risk, with focus now on core assets.LIDDSQ1 2025
- LIDDS AB posts zero sales, narrows losses, and pivots to partnerships after Noviga acquisition.LIDDSQ4 2024
LIDDS
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
LIDDS AB is a Swedish pharmaceutical company that focuses on drug delivery technologies, particularly for cancer treatment. Its proprietary technology, NanoZolid, enables localized and controlled release of drugs for up to six months, reducing systemic side effects. LIDDS leverages this platform to develop its own oncology-focused pipeline, which includes candidates such as Nanodotax (a NanoZolid-formulated chemotherapy) and Nanoimod (a TLR9 agonist for cancer immunotherapy). The company's strategy also involves partnering with other pharmaceutical firms to enhance drug efficacy and safety using its drug delivery technology. LIDDS is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.